Lesson plan
SW033291
SW033291 (PGDHi) is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The (R) or (+) enantiomer is more active, though much of the earlier research used the racemic mix. It increases levels of prostaglandin E2 and promotes tissue regeneration, and has shown beneficial effects for numerous potential medical applications in animal studies, including recovery from bone marrow transplant, acute kidney injury, liver damage, diabetes, heart failure, cartilage regrowth, sarcopenia, and neurological conditions such as Alzheimer's disease and traumatic brain injury.
Article summary
SW033291 (PGDHi) is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The (R) or (+) enantiomer is more active, though much of the earlier research used the racemic mix. It increases levels of prostaglandin E2 and promotes tissue regeneration, and has shown beneficial effects for numerous potential medical applications in animal studies, including recovery from bone marrow transplant, acute kidney injury, liver damage, diabetes, heart failure, cartilage regrowth, sarcopenia, and neurological conditions such as Alzheimer's disease and traumatic brain injury.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.